Abouzayed, A.; Borin, J.; Lundmark, F.; Rybina, A.; Hober, S.; Zelchan, R.; Tolmachev, V.; Chernov, V.; Orlova, A.
The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity. Diagnostics 2023, 13, 1611.
https://doi.org/10.3390/diagnostics13091611
AMA Style
Abouzayed A, Borin J, Lundmark F, Rybina A, Hober S, Zelchan R, Tolmachev V, Chernov V, Orlova A.
The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity. Diagnostics. 2023; 13(9):1611.
https://doi.org/10.3390/diagnostics13091611
Chicago/Turabian Style
Abouzayed, Ayman, Jesper Borin, Fanny Lundmark, Anastasiya Rybina, Sophia Hober, Roman Zelchan, Vladimir Tolmachev, Vladimir Chernov, and Anna Orlova.
2023. "The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity" Diagnostics 13, no. 9: 1611.
https://doi.org/10.3390/diagnostics13091611
APA Style
Abouzayed, A., Borin, J., Lundmark, F., Rybina, A., Hober, S., Zelchan, R., Tolmachev, V., Chernov, V., & Orlova, A.
(2023). The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity. Diagnostics, 13(9), 1611.
https://doi.org/10.3390/diagnostics13091611
